PIPELINE

Martell Diagnostic Laboratories, Inc. was formed to improve the management of cancer and advance exciting new technologies and solutions. Our commercial business model revolves around establishing a Minnesota-based national reference laboratory.

 

The first “product” is a blood test to monitor the course and treatment of HER2 breast cancer, the most aggressive form responsible for the majority of deaths. We recently began promoting HERTEST, a branded version of the sHER2/neu ELISA test. In addition, we are commercializing CHECKMARK, a blood test (serum) to measure soluble PD-L1, a biomarker of prognostic value in the management of lung, kidney and other cancers. We are developing ways to take these tests to the doctor’s office or  hospital--this will be accomplished using microfluidic immunoassays.

Microfluidic Reader

We are converting our CLIA laboratory from ELISA-based to microfluidic-based. This is the first step to providing our reference lab tests for hospital labs and doctors’ offices. It takes 10-14 days to receive most serum biomarker test reports. This could be reduced to one hour by using a novel microfluidic, cartridge-based test system. Thus, providing real-time data for assisting in therapy decisions.

Screen Shot 2019-05-16 at 2.43.17 PM.png

Our first system, developed in collaboration with an equipment manufacturer, uses their machine and custom cartridges with Martell's detection chemistry. Following this proof of concept we will engage a local medical device developer to assist in the design, build and manufacture of Martell's stand alone point-of-care microfluidic reader. During the design process we will also develop multiplexed cartridges to simultaneous measure several blood proteins; multiplexed microfluidics is the diagnostic methodology of the future.​